XOMA (NASDAQ:XOMA) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.40), MarketWatch Earnings reports. XOMA had a return on equity of 379.39% and a net margin of 43.55%. The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.83 million.
Shares of NASDAQ XOMA opened at $14.76 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 12.46 and a quick ratio of 12.46. The firm has a market cap of $107.44 million, a P/E ratio of 15.06 and a beta of 2.75. XOMA has a 1-year low of $11.88 and a 1-year high of $37.25.
A hedge fund recently raised its stake in XOMA stock. Bank of New York Mellon Corp raised its holdings in XOMA Corp (NASDAQ:XOMA) by 50.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,661 shares of the biotechnology company’s stock after buying an additional 12,002 shares during the quarter. Bank of New York Mellon Corp owned about 0.43% of XOMA worth $745,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 43.49% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “XOMA (XOMA) Posts Earnings Results, Misses Estimates By $0.40 EPS” was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/09/xoma-xoma-posts-earnings-results-misses-estimates-by-0-40-eps.html.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.